Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-edotreotide versus everolimus in progressive SSTR-positive GEP-NET
NL-OMON52990Phase 3Recruiting
- Sponsor
- ITM Isotope Technologies Munich
- Start
- Apr 2019
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Gastroenteropancreatic Carcinoid Tumor, islet cell tumor and gastrointestinal neuroendocrine neoplasm (GI-NEN) comparing 177Lu-edotreotide with Everolimus (2 arms). Primary endpoint: Progression-free survival. Started Apr 2019; status: recruiting.
02
Drugs
lutetium Lu 177-edotreotideeverolimus
03
Conditions
Gastroenteropancreatic Carcinoid Tumorislet cell tumorgastrointestinal neuroendocrine neoplasm (GI-NEN)
Beyond the preview
Go deeper on NL-OMON52990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52990.